CARBIDOPA-LEVODOPA (carbidopa/levodopa)
ANTIPARKINSONIAN LEVODOPA FORMULATIONS · PARKINSONISM ·+2
TEVA USA
Drug class
Antiparkinsonian Levodopa Formulations
Antiparkinsonian levodopa formulations represent a clinical grouping of dopaminergic therapies designed to deliver levodopa across various pharmacokinetic delivery systems, frequently co-formulated with peripheral decarboxylase inhibitors such as carbidopa. Read more about Antiparkinsonian Levodopa Formulations
52 drugs in this class 36 manufacturers
Drugs in Antiparkinsonian Levodopa Formulations
CARBIDOPA-LEVODOPA ER (carbidopa/levodopa)
ANTIPARKINSONIAN LEVODOPA FORMULATIONS · PARKINSONISM ·+2
ACCORD HEALTHCA
CARBIDOPA-LEVODOPA-ENTACAPONE (carbidopa/levodopa/entacapone)
ANTIPARKINSONIAN COMT INHIBITORS · IDIOPATHIC PARKINSONISM
Mylan Pharmaceuticals
CARBIDOPA-LEVODOPA-ENTACAPONE (carbidopa/levodopa/entacapone)
ANTIPARKINSONIAN COMT INHIBITORS · IDIOPATHIC PARKINSONISM
SANDOZ
DUOPA (carbidopa/levodopa)
ANTIPARKINSONIAN LEVODOPA FORMULATIONS · IDIOPATHIC PARKINSONISM
ABBOTT
CARBIDOPA-LEVODOPA (carbidopa/levodopa)
ANTIPARKINSONIAN LEVODOPA FORMULATIONS · PARKINSONISM ·+2
LIBERTAS PHARMA
RYTARY (carbidopa/levodopa)
ANTIPARKINSONIAN LEVODOPA FORMULATIONS · PARKINSONISM ·+2
GEMINI LABORATO
SINEMET (carbidopa/levodopa)
ANTIPARKINSONIAN LEVODOPA FORMULATIONS · PARKINSONISM ·+2
ORGANON LLC
DHIVY (carbidopa/levodopa)
ANTIPARKINSONIAN LEVODOPA FORMULATIONS · PARKINSONISM ·+2
AVION PHARMACEU
Filter & compare in the drug finder →
Opens the drug finder with Antiparkinsonian Levodopa Formulations preselected. Add indication or manufacturer filters there.
Antiparkinsonian levodopa formulations represent a clinical grouping of dopaminergic therapies designed to deliver levodopa across various pharmacokinetic delivery systems, frequently co-formulated with peripheral decarboxylase inhibitors such as carbidopa.
Although not a formal standalone regulatory class name, this category encompasses immediate-release, extended-release, enteral suspension, and inhaled formulations.
These agents serve as metabolic precursors that cross the blood-brain barrier to undergo enzymatic decarboxylation into dopamine, replenishing depleted striatal dopamine levels.
Primarily indicated as cornerstone therapy for Parkinson's disease and related parkinsonian syndromes, these varied delivery systems are engineered to optimize bioavailability, relieve cardinal motor symptoms, and mitigate motor fluctuations such as end-of-dose "wearing-off" episodes.
-
fda.gov
Antiparkinsonian levodopa formulations represent a clinical grouping of dopaminergic therapies designed to deliver levodopa across various pharmacokinetic delivery systems, frequently co-formulated with peripheral decarboxylase inhibitors such as carbidopa
-
nih.gov
Antiparkinsonian levodopa formulations represent a clinical grouping of dopaminergic therapies designed to deliver levodopa across various pharmacokinetic delivery systems, frequently co-formulated with peripheral decarboxylase inhibitors such as carbidopa Primarily indicated as cornerstone therapy for Parkinson's disease and related parkinsonian syndromes, these varied delivery systems are engineered to optimize bioavailability, relieve cardinal motor symptoms, and mitigate motor fluctuations s...
-
nv.gov
Antiparkinsonian levodopa formulations represent a clinical grouping of dopaminergic therapies designed to deliver levodopa across various pharmacokinetic delivery systems, frequently co-formulated with peripheral decarboxylase inhibitors such as carbidopa Although not a formal standalone regulatory class name, this category encompasses immediate-release, extended-release, enteral suspension, and inhaled formulations Primarily indicated as cornerstone therapy for Parkinson's disease and related ...
-
nih.gov
Although not a formal standalone regulatory class name, this category encompasses immediate-release, extended-release, enteral suspension, and inhaled formulations These agents serve as metabolic precursors that cross the blood-brain barrier to undergo enzymatic decarboxylation into dopamine, replenishing depleted striatal dopamine levels
-
drugbank.com
These agents serve as metabolic precursors that cross the blood-brain barrier to undergo enzymatic decarboxylation into dopamine, replenishing depleted striatal dopamine levels
-
apdaparkinson.org
These agents serve as metabolic precursors that cross the blood-brain barrier to undergo enzymatic decarboxylation into dopamine, replenishing depleted striatal dopamine levels
-
fda.gov
Primarily indicated as cornerstone therapy for Parkinson's disease and related parkinsonian syndromes, these varied delivery systems are engineered to optimize bioavailability, relieve cardinal motor symptoms, and mitigate motor fluctuations such as end-of-dose "wearing-off" episodes
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.